IL144043A0 - Reovirus for the treatment of cellular proliferative disorders - Google Patents

Reovirus for the treatment of cellular proliferative disorders

Info

Publication number
IL144043A0
IL144043A0 IL14404300A IL14404300A IL144043A0 IL 144043 A0 IL144043 A0 IL 144043A0 IL 14404300 A IL14404300 A IL 14404300A IL 14404300 A IL14404300 A IL 14404300A IL 144043 A0 IL144043 A0 IL 144043A0
Authority
IL
Israel
Prior art keywords
reovirus
treatment
proliferative disorders
cellular proliferative
cellular
Prior art date
Application number
IL14404300A
Other languages
English (en)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of IL144043A0 publication Critical patent/IL144043A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14404300A 1999-02-24 2000-02-18 Reovirus for the treatment of cellular proliferative disorders IL144043A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/256,824 US6136307A (en) 1997-08-13 1999-02-24 Reovirus for the treatment of cellular proliferative disorders
PCT/CA2000/000178 WO2000050051A2 (en) 1999-02-24 2000-02-18 Reovirus for the treatment of cellular proliferative disorders

Publications (1)

Publication Number Publication Date
IL144043A0 true IL144043A0 (en) 2002-04-21

Family

ID=22973731

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14404300A IL144043A0 (en) 1999-02-24 2000-02-18 Reovirus for the treatment of cellular proliferative disorders
IL144043A IL144043A (en) 1999-02-24 2001-06-28 Use of reovirus for the preparation of a pharmaceutical composition for the treatment of cellular proliferative disorders
IL197903A IL197903A (en) 1999-02-24 2009-04-05 A pharmacovigilance containing riavirus to treat cell culture disorders and its kit

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL144043A IL144043A (en) 1999-02-24 2001-06-28 Use of reovirus for the preparation of a pharmaceutical composition for the treatment of cellular proliferative disorders
IL197903A IL197903A (en) 1999-02-24 2009-04-05 A pharmacovigilance containing riavirus to treat cell culture disorders and its kit

Country Status (17)

Country Link
US (8) US6136307A (de)
EP (2) EP1949905A1 (de)
JP (1) JP2002537344A (de)
AR (1) AR022734A1 (de)
AT (1) ATE400283T1 (de)
AU (1) AU776401C (de)
CA (1) CA2360833C (de)
DE (1) DE60039415D1 (de)
DK (1) DK1156813T3 (de)
ES (1) ES2308971T3 (de)
HK (1) HK1039752B (de)
IL (3) IL144043A0 (de)
MX (1) MXPA01008457A (de)
NZ (2) NZ529362A (de)
PT (1) PT1156813E (de)
TW (1) TWI290467B (de)
WO (1) WO2000050051A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CA2720361A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) * 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
CN1250711C (zh) * 2000-06-26 2006-04-12 威尔斯达特生物制剂公司 用病毒清除细胞
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DK2189162T3 (da) 2000-11-09 2014-02-03 Oncolytics Biotech Inc Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
IL154758A0 (en) * 2000-11-20 2003-10-31 Oncolytics Biotech Inc Method for optimally delivering virus to a solid tumor mass
EP1339736A2 (de) * 2000-12-01 2003-09-03 University Of Ottawa Onkolytische viren
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7223388B2 (en) * 2001-08-03 2007-05-29 Board Of Regents, The Univeristy Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
EP1944035A1 (de) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Verfahren zur Schmerzlinderung durch onkolytische Viren
WO2003094938A1 (en) * 2002-05-09 2003-11-20 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
PT1505993E (pt) * 2002-05-10 2012-05-15 Oncolytics Biotech Inc Sensibilização de células neoplásicas a terapia de radiação com vírus oncolíticos
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2004096126A2 (en) * 2003-04-25 2004-11-11 Wellstat Biologics Corporation Treating hepatocellular carcinomas using therapeutic viruses
WO2005047458A2 (en) 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
WO2005112966A1 (en) * 2004-05-21 2005-12-01 Orison Biotechnology Inc. Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US7828978B2 (en) * 2006-01-11 2010-11-09 Doug Geier Simultaneous synthesis and purification of a fatty acid monoester biodiesel fuel
AU2007215328A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
JP5577103B2 (ja) * 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
EP2173368A1 (de) * 2007-07-18 2010-04-14 Genelux Corporation Verwendung eines chemotherapeutischen mittels zur herstellung eines medikaments zur behandlung oder linderung einer mit einer onkolytischen virentherapie verbundenen unerwünschten nebenwirkung
EP2211880A4 (de) * 2007-10-22 2012-11-14 Oncolytics Biotech Inc Behandlungsverfahren für proliferative erkrankungen
EP2300023A2 (de) * 2008-05-16 2011-03-30 Genelux Corporation Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
WO2015070323A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
WO2016065330A1 (en) 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
EP3911333A1 (de) 2019-01-18 2021-11-24 Université catholique de Louvain Viruszusammensetzungen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
PT70556A (en) 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
US4490358A (en) 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
EP0448650A4 (en) * 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
WO1990011765A1 (en) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
DK0931830T3 (da) * 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
US5525342A (en) 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5614403A (en) * 1994-06-01 1997-03-25 Baylor College Of Medicine In vitro replication system capable of rescuing cloned and manipulated rotavirus genes
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
AU4352997A (en) * 1996-08-30 1998-03-19 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
NZ503664A (en) 1997-10-09 2002-08-28 Pro Virus Inc A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
PT1505993E (pt) * 2002-05-10 2012-05-15 Oncolytics Biotech Inc Sensibilização de células neoplásicas a terapia de radiação com vírus oncolíticos
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2006287052B2 (en) * 2005-08-31 2009-03-12 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
JP5577103B2 (ja) * 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス

Also Published As

Publication number Publication date
PT1156813E (pt) 2008-09-02
US6811775B2 (en) 2004-11-02
IL197903A (en) 2014-02-27
JP2002537344A (ja) 2002-11-05
US20080026048A1 (en) 2008-01-31
WO2000050051A2 (en) 2000-08-31
US20110014155A1 (en) 2011-01-20
IL144043A (en) 2009-12-24
EP1156813A2 (de) 2001-11-28
DK1156813T3 (da) 2008-10-13
ATE400283T1 (de) 2008-07-15
US20030003080A1 (en) 2003-01-02
CA2360833A1 (en) 2000-08-31
US6136307A (en) 2000-10-24
US8071087B2 (en) 2011-12-06
EP1949905A1 (de) 2008-07-30
MXPA01008457A (es) 2002-06-21
WO2000050051A3 (en) 2000-12-28
US8709443B2 (en) 2014-04-29
US20120141426A1 (en) 2012-06-07
EP1156813B1 (de) 2008-07-09
NZ529362A (en) 2005-03-24
US8066985B2 (en) 2011-11-29
AU776401B2 (en) 2004-09-09
HK1039752B (en) 2008-11-21
ES2308971T3 (es) 2008-12-16
TWI290467B (en) 2007-12-01
CA2360833C (en) 2008-05-13
AU776401C (en) 2005-04-28
US20090117082A1 (en) 2009-05-07
NZ512661A (en) 2004-04-30
AU2788100A (en) 2000-09-14
US20050063954A1 (en) 2005-03-24
DE60039415D1 (de) 2008-08-21
US7374752B2 (en) 2008-05-20
AR022734A1 (es) 2002-09-04
US6455038B1 (en) 2002-09-24
HK1039752A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AU7621801A (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
IL197903A (en) A pharmacovigilance containing riavirus to treat cell culture disorders and its kit
ZA200107291B (en) Use of xenon for treating neurointoxications.
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
IL142950A0 (en) Device for the treatment of macular degeneration
IL154881A0 (en) Methods for the treatment of cellular proliferative disorders
HRP20020253A2 (en) Compounds for the treatment of ischemia
IL151132A0 (en) Pteridine compounds for the treatment of psoriasis
EP1404343A4 (de) Therapeutische kombinationen zur behandlung von hormonmangelzuständen
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
EP1207874A4 (de) Verfahren zur behandlung der proliferativen erkrankungen
HUP0200738A3 (en) Method of the treatment of incontinence
PL357812A1 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU8322401A (en) Indole compounds useful for the treatment of cancer
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
IL155769A0 (en) Method for the treatment of inflammation
GB0000113D0 (en) The use of triazolo-pyridazine derivatives for treating premenstrual syndrome
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
AU3899100A (en) Treatment of hyperactivity disorders
HRP20020262B1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
GB9904252D0 (en) Composition for the treatment of pain
AU1592901A (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)